Foundations Investment Advisors LLC Acquires Shares of 6,114 Sanofi (NASDAQ:SNY)

Key Points

• Foundations Investment Advisors LLC made a new investment of approximately $339,000 in Sanofi, acquiring 6,114 shares during the first quarter of the year.
• Several institutional investors, including Cardinal Capital Management and Gradient Investments LLC, have also increased their stakes in Sanofi, reflecting growing institutional interest.
• Sanofi reported earnings per share of $0.90 for the last quarter, missing expectations, while its revenue of $11.34 billion surpassed forecasts, though it still represents a 7% year-over-year decline.

Foundations Investment Advisors LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 6,114 shares of the company's stock, valued at approximately $339,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Invesco Ltd. increased its holdings in shares of Sanofi by 3.5% in the fourth quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after purchasing an additional 408,752 shares during the period. Bank of America Corp DE increased its holdings in Sanofi by 3.8% in the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock worth $579,587,000 after buying an additional 441,637 shares during the period. Price T Rowe Associates Inc. MD raised its position in Sanofi by 88.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after buying an additional 5,091,304 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in Sanofi by 1.0% during the 4th quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company's stock valued at $177,304,000 after acquiring an additional 34,660 shares during the period. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of Sanofi by 6.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company's stock valued at $181,764,000 after acquiring an additional 211,641 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Price Performance

Shares of NASDAQ:SNY traded up $1.11 during midday trading on Friday, reaching $46.75. 2,518,877 shares of the company's stock traded hands, compared to its average volume of 2,247,996. The company has a fifty day simple moving average of $49.10 and a two-hundred day simple moving average of $52.11. Sanofi has a 1 year low of $44.73 and a 1 year high of $60.12. The company has a market cap of $114.80 billion, a P/E ratio of 11.24, a PEG ratio of 1.12 and a beta of 0.48. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business's revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.73 earnings per share. Equities analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SNY. BNP Paribas initiated coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a report on Saturday. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Finally, Morgan Stanley set a $56.00 price target on shares of Sanofi in a report on Monday, June 2nd. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.